MAO阻害剤Safrazineの使用経験
スポンサーリンク
概要
- 論文の詳細を見る
The results of our clinical experiments on a new MAO inhibittor, SAFRAZlNE, were as follows : 1. Good results were obtained in 4 out 18 patients suffered from various depressive states; 4 were remarkably improved, and 5 were partially improved. Five patients remained unchanged or became worse. 2. Remarkable improvement was obtained in endogenous depression as well as involutional depression. In neurotic depression, noticeable improvement was observed, but no or only partial improvement was observed in depressive states in schizophrenia. 3. The response to the drug was considerably fast : in most cases the improvement was obseved within one week and the administration was through within five weeks. The daily dosage of less than 30 mg. was enough to obtain good results. 4. Of various depressive states, Safrazine was particularly effective for such intrinsic symptom as inhibition, depressive feeling, pessimism, and self-accusation. It seemed that each of those symptoms was evenly and simultaneously improved and that a separation of inhibition and depressive feeling was not observed. 5. Noticeable side reactions were reduction of blood pressure 1evel, dizziness, acceleration of tendon reflex, insomnia, thirst, vision disturbance or disorder, and psychomotor excitement, but none of them were serious. However, care should be taken about the collapse due to reduction of blood pressure level, when administered hypotensive or advanced-aged patients. No untoward side effect was found in hepatic function during our experiments. SAFRAZINE is superior to any other hydrazine derivatives in many respects and is of clinical value as an excellent antidepressant.
- 日本心身医学会の論文
- 1965-06-01